|
Volumn 8, Issue 9, 2012, Pages 482-483
|
Stroke: Expanded indications for stroke thrombolysisĝ€"what next?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALTEPLASE;
ANTITHROMBOCYTIC AGENT;
DESMOTEPLASE;
PLACEBO;
TENECTEPLASE;
ABSENCE OF SIDE EFFECTS;
BRAIN HEMORRHAGE;
BRAIN ISCHEMIA;
CLINICAL EFFECTIVENESS;
DISEASE ASSOCIATION;
DOSE RESPONSE;
DRUG EFFECT;
DRUG EFFICACY;
DRUG FATALITY;
DRUG INDICATION;
DRUG MEGADOSE;
DRUG SAFETY;
EARLY INTERVENTION;
EVIDENCE BASED MEDICINE;
FIBRINOLYTIC THERAPY;
FUNCTIONAL ASSESSMENT;
GROUPS BY AGE;
HUMAN;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SHORT COURSE THERAPY;
SHORT SURVEY;
STROKE;
THERAPY DELAY;
CLINICAL TRIALS AS TOPIC;
FIBRINOLYTIC AGENTS;
HUMANS;
STROKE;
THROMBOLYTIC THERAPY;
TIME FACTORS;
TISSUE PLASMINOGEN ACTIVATOR;
|
EID: 84866087039
PISSN: 17594758
EISSN: 17594766
Source Type: Journal
DOI: 10.1038/nrneurol.2012.151 Document Type: Short Survey |
Times cited : (6)
|
References (10)
|